Definium Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
DFTX$34.64-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands) | 2026 | 2025 |
| Cash flows from operating activities | ||
| Net loss | $(77,098) | $(23,348) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 7,132 | 3,426 |
| Change in fair value on directors' deferred share units ("DDSU") | 1,030 | (18) |
| Change in fair value of the 2022 USD Financing Warrants | 20,046 | (6,999) |
| Amortization of discounts and premiums on investments, net | 591 | — |
| Other non-cash adjustments | 220 | (19) |
| Changes in operating assets and liabilities: | ||
| Prepaid and other current assets | 585 | (1,380) |
| Other noncurrent assets | 118 | (10) |
| Accounts payable | 1,780 | 258 |
| Accrued expenses | 2,994 | (1,329) |
| Other liabilities, long-term | (29) | — |
| Net cash used in operating activities | (42,631) | (29,419) |
| Cash flows from investing activities | ||
| Purchases of investments | — | (162,458) |
| Maturity of investments | 42,000 | — |
| Net cash provided by (used in) investing activities | 42,000 | (162,458) |
| Cash flows from financing activities | ||
| Proceeds from exercise of pre-funded warrants | 4 | — |
| Proceeds from exercise of 2022 USD Financing Warrants | 3,833 | 579 |
| Proceeds from exercise of options | 1,196 | 237 |
| Proceeds from issuance of common shares under ESPP | 276 | 186 |
| Net cash provided by financing activities | 5,309 | 1,002 |
| Effect of exchange rate changes on cash | 3 | (12) |
| Net increase/(decrease) in cash and cash equivalents | 4,681 | (190,887) |
| Cash and cash equivalents, beginning of period | 257,837 | 273,741 |
| Cash and cash equivalents, end of period | $262,518 | $82,854 |
| Supplemental Cash Flow Information | ||
| Cash paid for interest and final payment for credit facility | $1,051 | $602 |
| Supplemental Noncash Disclosures | ||
| Conversion of 2022 USD Financing Warrants to common shares upon exercise of warrants | 11,480 | 295 |
| Lease liabilities arising from obtaining right-of-use assets | 135 | — |
| Amortization of deferred financing costs | 40 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.